Adalimumab Clinical Trial
Official title:
A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.
This was a Phase 3, multicenter, open-label, single-arm study of adalimumab in Japanese participants with generalized pustular psoriasis (GPP). The study included a 30-day screening period, a 52-week treatment period, and a 70-day follow-up period. The dose regimen of adalimumab used in this study was 80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04300686 -
A Pilot Study in Severe Patients With Takayasu Arteritis.
|
Phase 4 | |
| Recruiting |
NCT05590416 -
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
|
||
| Completed |
NCT05909852 -
A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05155592 -
Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients
|
Phase 2 | |
| Recruiting |
NCT05015335 -
The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
|
Phase 4 |